Alt a 1 Promotes Allergic Asthma In Vivo Through TLR4-Alveolar Macrophages
The mold Alternaria alternata is one of the main sources of asthma exacerbation, being its major allergen, Alt a 1, indispensable for its development. The main objective of this work was to answer two main questions: 1) can Alt a 1 by itself (without any other context) induce an asthmatic profile in...
Saved in:
Published in: | Frontiers in immunology Vol. 13; p. 877383 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Frontiers Media S.A
30-06-2022
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The mold
Alternaria alternata
is one of the main sources of asthma exacerbation, being its major allergen, Alt a 1, indispensable for its development. The main objective of this work was to answer two main questions: 1) can Alt a 1 by itself (without any other context) induce an asthmatic profile
in vivo
?; and 2) Which molecular mechanisms take place during this phenomenon? To answer both questions, we have developed a mouse model of allergic asthma using only Alt a 1 for mice sensitization. We also made use of
in-vitro
cellular models and computational studies to support some aspects of our hypothesis. Our results showed that Alt a 1 can induce an asthmatic phenotype, promoting tissue remodeling and infiltration of CD45+ cells, especially eosinophils and macrophages (Siglec F+ and F4/80+). Also, we have found that Alt a 1 sensitization is mediated by the TLR4-macrophage axis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology Edited by: Cong-Yi Wang, Tongji Medical College, China Reviewed by: Fei Sun, Tongji Medical College, China; Weining Xiong, Shanghai Ninth People’s Hospital Ninth, China |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2022.877383 |